Fresh Off Phase III, Revolution Presents Positive Frontline Daraxonrasib Data

 
• By Alaric DeArment
  
Revolution Medicines is presenting data for daraxonrasib in frontline pancreatic ductal adenocarcinoma. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Commercial Strategy

More from Business